The headset, developed by researchers at Cornell University in New York, could help reveal how the brain navigates and ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...

Discover how a groundbreaking cognitive assessment tool is transforming early dementia detection with 99.9% accuracy and what this means for future treatment.

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Dementia cases in the U.S. are expected to double by 2060, with an estimated one million people diagnosed per year, according ...

Acadia Pharmaceuticals Inc. today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett ...

A Potential Game-Changer for Mental Health TreatmentsSetting New Benchmarks: 65% Response Rate Shown in Completed Depression ...